Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00681395

Enrollment

Registered

2008-05-21

Start date

2008-05-31

Completion date

Unknown

Last updated

2012-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Events, Pharmacokinetic

Brief summary

To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Interventions

DRUGABT-143

once daily for 6 days

DRUGABT-335

once daily for six days

DRUGRosuvastatin

Once daily for 6 days

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* General good health * BMI 19 to 29

Exclusion criteria

* Currently enrolled in another study * Females who are pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
Adverse event and safety laboratory assessments	7 days
Pharmacokinetic parameters	7 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026